LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Valerie W. McClain, IBCLC" <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Tue, 1 Oct 2002 06:14:54 EDT
Content-Type:
text/plain
Parts/Attachments:
text/plain (106 lines)
I thought for those who were interested in the recent asthma study in the 
Lancet might be interested in this news release that GlaxoSmithKline Inc. 
recently invested $1 million in McMaster University to establish a research 
chair in pediatric asthma at the Firestone Institute for Respiratory Health 
St. Joseph's Healthcare Hamilton, Ontario, Canada.  What a coincidence that 
Malcolm Sears lead author for the study that shows that breastfeeding is a 
risk for asthma is employed at that very same Institute in Hamilton Ontario.  
What a small world.  Valerie W. McClain, IBCLC


http://www.ths.mcmaster.ca/pubrel/gsk.htm

HAMILTON – (June 18, 2002) – GlaxoSmithKline Inc. today announced a $1 
million investment to establish a McMaster University Research Chair in 
pediatric asthma at the Firestone Institute for Respiratory Health, St. Joseph
’s Healthcare Hamilton. The creation of this Chair is part of the 
GlaxoSmithKline Pathfinders Fund for Leaders in Canadian Health Science 
Research, a $10 million initiative to help fight the brain drain in Canada by 
providing opportunities for leading medical researchers and scientists. The 
GlaxoSmithKline Chair in Pediatric Asthma will enable the Firestone Institute 
to create a permanent position, allowing the recipient to conduct research 
that will improve the understanding of this chronic disease and potentially 
lead to pioneering new treatments for Canadian children with asthma. “This is 
an important research investment into a disease that has a tremendous impact 
on all segments of the population, but especially children,” said Paul Lucas, 
President and CEO of GlaxoSmithKline Inc. “As a company, we have been a 
leader in the treatment of asthma for more than 30 years, working with 
organizations like the Firestone Institute for Respiratory Health to improve 
the understanding and management of asthma in Canada. This investment is part 
of our longstanding commitment to asthma research.” “The work being done in 
the Faculty of Health Sciences at McMaster University rivals any in Canada, 
and this Chair will expand that reputation,” said Dr. Peter George, President 
of McMaster University. “It will allow us to continue to attract leading 
scientists and provide an enriching environment to encourage world-class 
research, and also affirms our strong partnership with St. Joseph's 
Healthcare and the Firestone Institute for Respiratory Health.” Asthma is a 
chronic lung disease resulting in recurrent attacks of breathlessness, 
generally accompanied by wheezing, chest tightness and/or coughing. The 
disease affects more than 2 million Canadians, including an estimated 10 to 
15 per cent of Canada’s children. In Canada, asthma is among the most common 
causes of emergency room visits, hospitalizations and unscheduled doctor 
visits. It is also the most common reason that children miss school. 
Approximately 450 Canadians die each year from asthma, and it is estimated 
that more than 80 per cent of these deaths could be prevented with proper 
asthma education and treatment. “This Research Chair recognizes the role of 
the Firestone Institute in providing leading-edge research into asthma and 
other respiratory diseases,” said Dr. Paul O’Byrne, Director of the 
Firestone Institute for Respiratory Health and Head of the Division of 
Respiratory Medicine at McMaster University. “The investment will enable the 
future recipient of this Research Chair to establish a world-class centre for 
the study of pediatric asthma.” “Asthma has a tremendous impact on both 
children and their families, and is a leading cause of hospitalization for 
children,” said Dr. Kevin Smith, President & CEO, St. Joseph’s Healthcare. “
The focus of this Chair in pediatric asthma will further enhance the 
leadership of the Firestone Institute for Respiratory Health and lead to 
important advancements in our knowledge and understanding of this 
debilitating disease.” The Research Chair has been established through 
GlaxoSmithKine’s Pathfinders Fund for Leaders in Canadian Health Science 
Research. In the past two years, chairs and professorships have been 
appointed at Canadian research institutes in areas including genetics, 
stroke, and the diseases of aging. The Pathfinders Fund also supports a 
Research Chair in Gastroenterology at McMaster University. “We are excited 
about supporting pioneering research at McMaster University as part of our 
efforts to fight disease and save lives,” said Dr. Anne Phillips, 
GlaxoSmithKline’s Vice President of Research & Development. “This donation 
is part of the Pathfinders Fund, established to create research positions in 
all Canadian medical schools and to encourage researchers and scientists to 
conduct their important discovery work in Canada.” About The Partners The 
Firestone Institute for Respiratory Health was one of Canada’s first 
initiatives in which a hospital and a university developed a major ambulatory 
care model for out-of-hospital investigation and treatment of patients with 
lung disease. This model is still in use today where Firestone’s clinicians 
and allied health professionals are working to advance research that will 
eventually lead to innovations in the care and treatment of lung disease. In 
addition to focusing on research and teaching, more than 21,000 patients 
visit the Firestone Institute’s clinics each year for leading-edge care. The 
Firestone Institute is part of St. Joseph’s Healthcare Hamilton, a 600-plus 
acute care, teaching and research hospital affiliated with the Faculty of 
Health Sciences at McMaster University and Mohawk College. The Faculty of 
Health Sciences at McMaster University is one of the leading research 
institutes in the world. Located in Hamilton, Ontario, the Faculty is 
internationally recognized for its innovative approach to health care 
education, evidence-based medicine, and clinical, basic and genomic research. 
GlaxoSmithKline Inc. – one of the world's leading research-based 
pharmaceutical and healthcare companies – is committed to improving the 
quality of human life by enabling people to do more, feel better and live 
longer. In Canada, GlaxoSmithKline employs more than 1,800 people and is a 
top 20 investor in Canadian research and development, contributing more than 
$100 million annually. The company is also one of the top 10 corporate 
charitable donors, investing more than $6.5 million annually and is 
recognized as one of the 50 best companies to work for in Canada 



             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2